Auxilium Pharmaceuticals — Investor Presentation (January 2010)
44 slides from Auxilium Pharmaceuticals's investor presentation, Jan 11, 2010
Slide 1: January 2010 Investor Presentation
January 2010 Exhibit 99.1 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth XIAFLEX New Territories XIAFLEX New Indications XIAFLEX Peyronie’s XIAFLEX Dupuytren’s Testim
Slide 4: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy
Slide 5: XIAFLEX
XIAFLEX XIAFLEX product and packaging have not been approved by the FDA
Slide 6: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease Well-characterized mode of action State of the art biological manufacturing facility Worldwide rights generate and
Slide 7: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients Excessive collagen deposition in fascia of hand Nodules represent early, active form Cords develop over time, are palpable, and result in contractures Quality of life and daily activities can be significantly affected Surgery may be reserved for a
Slide 8: Current Treatment Options Require Invasive Surgery or Are Unapproved and Ineffective
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective Surgery Non-surgical options > Splinting > Physical therapy > Corticosteroids Needle fasciotomy/ aponeurotomy Amputation
Slide 9: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product
Slide 10: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture Primary endpoint is reduction in contracture to within - 5 of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints Secondary
Slide 11: Results Are Comparable to Surgery at the Joint Level
Results Are Comparable to Surgery at the Joint Level Hurst et al. NEJM 2009 Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) P < 0.001 P < 0.001 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) P < 0.001 MP = metacarpophal
Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 9 days across studies Severe Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of >2600
Slide 13: XIAFLEX is a Potential, First-line Nonsurgical Option for Dupuytren's Contracture
XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture Efficacy should compare favorably to surgery – Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake E
Slide 14: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 15: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years Method of Use Patent in U.S. through 2014 Use Patent in France,
Slide 16: XIAFLEX Supply Chain
XIAFLEX Supply Chain API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand Fill and Lyophilization
Slide 17: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture – an Unmet Medical Need NEJM 2009 Hueston 1963 Skoog 1948 Mikkelsen 1976 Tubiana 2006 Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations Higher prevalence in patients of northern-European d
Slide 18: Extensive Market Research Performed with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons Multiple prevalence data sets proved to be highly variable in numbers of patients Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture A combined 571 Orthopedic Surgeons hav
Slide 19: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis
Slide 20: XIAFLEX Pricing Recommendations Derived From Key Stakeholder Drivers
XIAFLEX Pricing Recommendations* Derived From Detailed Assessment Of Key Stakeholder Drivers DRIVERS: Financial risk vs. return On per hour basis, could provide reimbursement on par with surgery Shorter procedure to allow larger volumes to be treated and free up time for other procedures *XIAFLEX Pr
Slide 21: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU Sustainable patient pool – New patients within an ageing population Avera
Slide 22: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Scarring phenomenon affecting the tunica albuginea Plaques show excessive collagen deposition Potential Symptoms > Pain with erection, penile curvature/ deviati
Slide 23: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Prevalence of Peyronie’s disease is estimated at in adult men > Actual prevalence may be higher, based on autopsies Prevalence rate increases with age > The average age of disease onset is years High association with other diseases such as: > Diabetes, erec
Slide 24: Peyronie's Phase IIb Study Designed To Assess Safety And Efficacy
Peyronie’s Phase IIb Study Designed To Assess The Safety And Efficacy With XIAFLEX Study design: – XIAFLEX was administered two times a week every six weeks for up to three treatment cycles (2 x 3) – 145 patients at 12 U.S. sites Patients must have been able to maintain a rigid erection with a penil
Slide 25: Peyronie's Phase IIb Trial Utilized a Novel Patient Reported Outcome
Peyronie’s Phase IIb Trial Utilized a Novel Patient Reported Outcome (PRO) Study was designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. PRO measured four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyronie’s d
Slide 26: Promising Phase IIb Data in Peyronie's Disease
Promising Phase IIb Data in Peyronie’s Disease Overall – Significant XIAFLEX effect – Reduction of penile curvature – Improvement in Peyronie’s Disease Bother (PRO Domain) XIAFLEX With Modeling – Significant effect in both penile curvature and Peyronie’s disease bother endpoints XIAFLEX Without Mode
Slide 27: Mean Penile Curvature Improved Significantly
At 36 weeks, Mean Penile Curvature Improved Significantly
Slide 28: Overall Mean Score Change with Peyronie's Disease Bother Improved Significantly
At 36 weeks, Overall Mean Score Change with Peyronie’s Disease Bother Improved Significantly
Slide 29: Anticipated Next Steps for Peyronie's disease
Anticipated Next Steps for Peyronie’s disease End of Phase II meeting with FDA expected in 2Q10 to discuss: – Validation of PRO – Phase III trial design Anticipate commencing U.S. Phase III study in 2H10
Slide 30: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given feedba
Slide 31: Annually, >210,000 Peyronie's Candidates May Exist in U.S. and Europe
Annually , > 210,000 Peyronie’s Candidates May Exist in U.S. and Europe Source: 2006 Auxilium research and analysis
Slide 32: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval Market Exclusivity in EU could be extended to 11 years on approval of additional indication Method of Use Patent in U.S. through 2019 Use Patent Granted in France, U
Slide 33: Strategic Partnership with Pfizer for XIAFLEX in EU
Strategic Partnership with Pfizer for XIAFLEX in EU Strong working relationship with goal to obtain EMEA approval Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. Pfizer is primarily responsible for: European terri
Slide 34: Auxilium – Innovations for Life
_ AUXILIUM Innovations for Life™
Slide 35: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal*
Slide 36: 447% +30%
447% +30%
Slide 37: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) Nov. 2009 L12M: 28.1%
Slide 38: Testim Quarterly Net Revenues and Scripts Continuing Consistent Revenue Growth
Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 3Q09 Net Testim Revenues Y/Y Growth: +25.1% 3Q09 TRX Y/Y Growth: +17.3% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.2M $113.3M
Slide 39: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for Test
Slide 40: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic versions
Slide 41: Q3 '09 Financial Results and 2009 Guidance
Revenues $42.1 $116.0 $155-165 R&D Expense $12.8 $40.0 $45-50 SG&A Expense $34.7 $90.5 $120-130 Net Loss ($14.9) ($41.6) ($50-55) Stock – Based Comp Expense $4.1 $13.5 $16-19 Cash & Cash Equivalents $192.3 Q3 ‘09 Financial Results and 2009 Guidance ($ Millions) Q3 ’09 9M ‘09 Guidance Currently, appr
Slide 42: Strategic Priorities in 2010
Strategic Priorities in 2010 Execute a successful launch in the U.S. for XIAFLEX in Dupuytren’s contracture approximately 60 days after approval; Complete enrollment in the observational long term follow up study of Dupuytren’s contracture patients; Commence phase III for XIAFLEX in Peyronie’s disea
Slide 43: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 44: Auxilium Management Contact
Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com January 2010 (NASDAQ: AUXL)
Auxilium Pharmaceuticals — Investor Presentation (January 2010) on 6ix